BOTHELL, Wash., May 26, 2015 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced that it is a Gold Sponsor of the 2015 International Society for Cellular Therapy annual meeting, to be held from May 27^th – 30^th in Las Vegas, NV.  The Company is also participating in a number of events including:

• Sponsor of the Opening Welcome Reception – Wednesday, May 27th, 7:30 – 9:30 pm, Exhibition Hall
• Corporate Tutorial – Friday, May 29th, 12:45 – 1:45 pm – Aby J. Mathew PhD, BioLife Senior Vice President & Chief Technology Officer, presents Biopreservation, Biologistics, Patient Delivery, and Cell Thawing Media
• Strategies for Commercialization Track 5 – Friday, May 29th, 11:15 am – 12:30 pm – Biologistics: Optimizing Costs of Cold Supply Chain with panelist, Kevin O'Donnell, VP of Cold Chain Standards Practices & Compliance, BioLife/biologistex™
• Plenary Session Four – Friday, May 29th, 2:00-3:30 pm – Game Changers: Policy and Practice Changes Enabling the Commercialization of Cell and Tissue Products, Chair: Aby J. Mathew, PhD

BioLife will present and demonstrate the evo smart, precision thermal shipper and its connected, cloud hosted biologistex application which enables customers to pack, ship, and track high-value biologic based payloads including starting material for cell and tissue based products and manufactured cellular and regenerative medicine products and therapies.

Mike Rice, BioLife Solutions President & CEO, remarked on the Company's support for ISCT and activities at the 2015 annual meeting by stating, "We are thrilled to once again be a primary sponsor of the ISCT annual meeting.  ISCT supports groundbreaking research on potentially life saving cellular therapies and we look forward to seeing many customers and prospects at the conference.  We have worked very hard over the last several years to build awareness within the ISCT community about the need for improved biopreservation practices. In this, our most strategic market segment, I'm very pleased to see the adoption of CryoStor and HypoThermosol as best in class, clinical grade biopreservation media in now over 185 clinical development projects and clinical trials for new cellular therapies. We are also very pleased about the full launch of our new biologistex cloud based logistics management app and the evo smart, precision thermal shipper.  This cold chain management solution is an integrated system of highly disruptive technologies that we believe will improve several key quality metrics in the delivery practices of time and temperature sensitive biologic based materials."

More information about the conference can be found here: http://www.celltherapysociety.org/events/event_details.asp?id=494270

About ISCT

ISCT is a global association driving the translation of scientific research to deliver innovative cellular therapies to patients. ISCT is the only group focused on pre-clinical and translational aspects of developing cell therapy products. As such, ISCT helps academic, government and biotech/pharma sectors transform research into practice and product. For more information, please visit www.celltherapysociety.org.

About biologistex

biologistex CCM (Cold Chain Management) is a new joint venture formed by BioLife Solutions, Inc. and SAVSU Technologies, LLC, a wholly owned subsidiary of Barson Corporation.

A play on the word biologistics (defined as the processes, tools, and data used to monitor and manage the movement of biologic materials such as vaccines, cells, tissues, and organs across time and space), biologistex is poised to disrupt the 50 year old service chain for delivery logistics of biologic based materials through innovative, smart, precision thermal shipping containers and a cloud hosted logistics management application.

The entity is majority held by BioLife Solutions, with SAVSU Technologies being the only other shareholder. biologistex CCM was formed to leverage SAVSU intellectual property related to controlled temperature containers and BioLife's significant relationships and customer base in the high growth biobanking, drug discovery, and regenerative medicine markets.  biologistex CCM has received a 20-year exclusive worldwide distribution right to current and future SAVSU controlled temperature containers, including the EVO™ smart container. BioLife will make a multi-million dollar investment in connection with these transactions, and will manage all sales, marketing, technical, customer service, accounting, and fulfillment operations in its current Bothell, Washington facilities. For more information please visit www.biologistex.net.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cloud-hosted logistics management applications for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The Company's proprietary HypoThermosol^® and CryoStor^® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife's enabling technologies provide commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This press release contains forward-looking statements, including, but not limited to, statements concerning new products, the company's anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, and, projected financial results and liquidity. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; reliance upon SAVSU for completing the development and manufacturing of biologistex CCM's products; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor Relations
Daphne Taylor
Senior Vice President, Chief Financial Officer
(425) 402-1400
dtaylor@biolifesolutions.com

SOURCE BioLife Solutions, Inc.